# reload+after+2024-01-22 16:46:26.339194
address1§12230 El Camino Real
address2§Suite 300
city§San Diego
state§CA
zip§92130
country§United States
phone§858 434 1113
fax§858 408 3010
website§https://www.oncternal.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.
fullTimeEmployees§30
companyOfficers§[{'maxAge': 1, 'name': 'Dr. James B. Breitmeyer M.D., Ph.D.', 'age': 69, 'title': 'President, CEO & Director', 'yearBorn': 1954, 'fiscalYear': 2022, 'totalPay': 814673, 'exercisedValue': 0, 'unexercisedValue': 57617}, {'maxAge': 1, 'name': 'Dr. Salim  Yazji M.D.', 'age': 54, 'title': 'Chief Medical Officer', 'yearBorn': 1969, 'fiscalYear': 2022, 'totalPay': 549206, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Richard G. Vincent CPA', 'age': 59, 'title': 'CFO & Treasurer', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 524475, 'exercisedValue': 0, 'unexercisedValue': 82588}, {'maxAge': 1, 'name': 'Dr. Rajesh  Krishnan Ph.D.', 'age': 50, 'title': 'Chief Technical Officer', 'yearBorn': 1973, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Chase C. Leavitt', 'age': 41, 'title': 'General Counsel & Secretary', 'yearBorn': 1982, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Pablo  Urbaneja', 'title': 'Senior Vice President of Corporate Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Anita  Wiseth', 'title': 'Senior Vice President of Human Resources', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.4
priceToSalesTrailing12Months§1.53283
currency§USD
dateShortInterest§1702598400
forwardEps§-0.56
exchange§NCM
quoteType§EQUITY
shortName§Oncternal Therapeutics, Inc.
longName§Oncternal Therapeutics, Inc.
firstTradeDateEpochUtc§1075818600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§fb3086bb-6779-3bd2-a1c4-93604c12e1a6
gmtOffSetMilliseconds§-18000000
targetHighPrice§2.5
targetLowPrice§2.0
targetMeanPrice§2.17
targetMedianPrice§2.0
recommendationMean§2.2
recommendationKey§buy
numberOfAnalystOpinions§3
quickRatio§7.859
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
